Enlivex Therapeutics Ltd. (ENLV)

Market Cap	23.56M
Revenue (ttm)	n/a
Net Income (ttm)	-12.70M
Shares Out	24.29M
EPS (ttm)	-0.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,222,147
Open	0.9400
Previous Close	0.9000
Day's Range	0.9000 - 0.9800
52-Week Range	0.8313 - 2.1000
Beta	1.48
Analysts	Buy
Price Target	7.00 (+621.72%)
Earnings Date	Nov 28, 2025

About ENLV

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 12, 1995
• Employees: 71
• Stock Exchange: NASDAQ
• Ticker Symbol: ENLV
• Website: https://www.enlivex.com

Analyst Summary

According to 2 analysts, the average rating for ENLV stock is "Buy." The 12-month stock price target is $7.0, which is an increase of 621.72% from the latest price.

Price Target

$7.0

(621.72% upside)

Analyst Consensus: Buy